<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medical Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1752-1947</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24885603</article-id>
      <article-id pub-id-type="pmc">4055228</article-id>
      <article-id pub-id-type="publisher-id">1752-1947-8-147</article-id>
      <article-id pub-id-type="doi">10.1186/1752-1947-8-147</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of granulocyte colony-stimulating factor &#x2013; a potential neoplastic marker: a case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Kasi Loknath Kumar</surname>
            <given-names>Anup</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>anupdoc@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Satyan</surname>
            <given-names>Megha Teeka</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>meghaanup19@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Holzbeierlein</surname>
            <given-names>Jeffrey</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>jholzbeierlein@kumc.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Mirza</surname>
            <given-names>Moben</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>mmirza@kumc.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Van Veldhuizen</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>pvanveldhuizen@kumc.edu</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA</aff>
      <aff id="I2"><label>2</label>Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>5</month>
        <year>2014</year>
      </pub-date>
      <volume>8</volume>
      <fpage>147</fpage>
      <lpage>147</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>3</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Kasi Loknath Kumar et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Kasi Loknath Kumar et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.jmedicalcasereports.com/content/8/1/147"/>
      <abstract>
        <sec>
          <title>Introduction</title>
          <p>Granulocyte colony-stimulating factor produced by nonhematopoietic malignant cells is able to induce a leukemoid reaction by excessive stimulation of leukocyte production. Expression of granulocyte colony-stimulating factor and its functional receptors have been confirmed in bladder cancer cells. <italic>In vitro</italic> studies have demonstrated that granulocyte colony-stimulating factor/receptor exhibits a high affinity binding and this biological axis increases proliferation of the carcinoma. Urothelial carcinoma of the bladder is rarely associated with a leukemoid reaction and autocrine growth induced by paraneoplastic production of granulocyte colony-stimulating factor. In the world literature, there have been less than 35 cases reported in the last 35 years. The clinicopathological aspects, biology, prognosis and management of granulocyte colony-stimulating factor-secreting bladder cancers are poorly understood.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 39-year-old Caucasian woman with an invasive high-grade urothelial carcinoma presented with hematuria and low-grade fevers. Laboratory tests revealed an elevated white blood cell count and absolute neutrophil count and an elevated 24-hour urine protein. Upon further evaluation she was found to have locally advanced high-grade urothelial carcinoma without nodal or distant metastasis. Her serum granulocyte colony-stimulating factor level was 10 times the normal limit. This led to the diagnosis of a paraneoplastic leukemoid reaction. Her white blood cell count immediately normalized after cystectomy but increased in concordance with recurrence of her disease. Unfortunately, she rapidly progressed and expired within 10 months from the time of first diagnosis.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This is one of the few cases reported that illustrates the existence of a distinct and highly aggressive subtype of bladder cancer which secretes granulocyte colony-stimulating factor. Patients presenting with a leukemoid reaction should be tested for granulocyte colony-stimulating factor/receptor biological axis. Moreover, granulocyte colony-stimulating factor could be a potential neoplastic marker as it can follow the clinical course of the underlying tumor and thus be useful for monitoring its evolution. Neoadjuvant chemotherapy should be considered in these patients due to the aggressive nature of these tumors. With a better understanding of the biology, this autocrine growth signal could be a potential target for therapy in future.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Bladder cancer</kwd>
        <kwd>Granulocyte colony-stimulating factor</kwd>
        <kwd>Leukemoid reaction</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Paraneoplastic leukemoid reaction is a type of paraneoplastic syndrome in which there is an elevation in the white blood cell count, predominantly neutrophils. Granulocyte colony-stimulating factor (G-CSF) secreted by nonhematopoietic malignant cells has been reported to be able to induce a leukemoid reaction through excessive stimulation of leukocyte production [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Urothelial carcinoma of the bladder is rarely associated with a leukemoid reaction, with less than 30 cases reported over the past 30 years, some of which tried to elucidate the role of G-CSF [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. A previous study reported that 9.2% of bladder tumors are associated with high levels of G-CSF [<xref ref-type="bibr" rid="B8">8</xref>]. In addition, expression of G-CSF and functional G-CSF receptors (G-CSFR) has been demonstrated in bladder cancer cells [<xref ref-type="bibr" rid="B9">9</xref>]. <italic>In vitro</italic> studies have demonstrated that G-CSF/G-CSFR exhibit high affinity [<xref ref-type="bibr" rid="B1">1</xref>] binding and this biological axis increases proliferation in bladder cancer cells [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. This autocrine mechanism of growth may be associated with aggressive tumor growth and adverse clinical outcomes [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. Here, we present a rare case of a leukemoid reaction and autocrine growth of bladder cancer induced by paraneoplastic production of G-CSF. We review the literature on the main clinicopathological aspects of this important, but rare, condition and review the biology of G-CSF in bladder cancer and its implications for diagnosis, management, prognosis and future research.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 39-year-old non-cigarette-smoking Caucasian woman with hypertension, type 2 diabetes, diabetic retinopathy and neuropathy was diagnosed with muscle invasive high-grade urothelial carcinoma with squamous and glandular differentiation and necrosis by transurethral resection of her bladder tumor 4 months prior to presentation to our hospital. Three weeks prior to presentation in our clinic she had noted gross hematuria, daily low-grade fevers, night sweats and weight gain of 32kg. A physical examination revealed that her temperature was 39&#xB0;C (102.2&#xB0;F), pulse 110 per minute, respiratory rate 20 per minute, and blood pressure 150/83mmHg. Her examination was only remarkable for progressive anasarca. Laboratory studies revealed elevated white blood cell (WBC) count and absolute neutrophil count (ANC; peak WBC 57.8K/UL, peak ANC 43.24K/UL), leukocyte alkaline phosphatase score 295, erythrocyte sedimentation rate (ESR) &gt;140mm/hour, C-reactive protein (CRP) 29.5mg/dL, and antineutrophilic antibody (ANA) titer 320. She also had nephrotic range proteinuria with 24-hour urine protein of 14.65g and a serum creatinine of 3.27mg/dL (Table&#xA0;<xref ref-type="table" rid="T1">1</xref> and Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). On admission, her urine grew greater than 100,000 <italic>Aerococcus urinae</italic> for which she was treated with a course of ceftriaxone. Repeat urine and blood cultures were negative but she had continued elevation of her WBC count. The results of anti-double stranded deoxyribonucleic acid (DNA) antibody, rheumatic factor, anti-SSA, anti-SSB, anti-glomerular basement membrane, myeloperoxidase, proteinase 3, cytoplasmic antineutrophil cytoplasmic antibody, perinuclear antineutrophil cytoplasmic antibody, hepatitis panel, and human immunodeficiency virus antibody tests were negative. Serum protein electrophoresis, creatine phosphokinase, quantitative immunoglobulin assay, complement levels and chest radiograph were all normal. Hence, symptoms, signs and laboratory studies were negative for an infectious etiology (including a tagged WBC scan) and autoimmune/rheumatological disease. A bone scan and positron emission tomography scan ruled out metastasis (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>). A computed tomography (CT) scan showed a large nodular bladder mass (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>). The fevers and night sweats were attributable to her malignancy and her weight gain/anasarca was related to her nephrotic syndrome. After her medical condition was optimized, she underwent a radical cystectomy, bilateral pelvic lymph node dissection, and ileal conduit urinary diversion along with total abdominal hysterectomy/bilateral salpingo-oophorectomy. Immediately after removal of her bladder tumor, her presenting symptoms and laboratory values improved remarkably. Fevers and night sweats completely resolved. Her WBC count was 6.8K/UL, ANC 5.05K/UL, ESR 45mm/hour, CRP 6.89mg/dL, ANA &lt;80, 24-hours urine proteins of 5.25g, and serum creatinine 1.30mg/dL (Table&#xA0;<xref ref-type="table" rid="T1">1</xref>). Histopathology revealed poorly differentiated high-grade transitional cell carcinoma invading the entire bladder wall and the myometrium of the lower uterine segment along with vascular invasion without metastasis. Her pathologic staging was pT4a,N0,M0 (Figure&#xA0;<xref ref-type="fig" rid="F4">4</xref>). In addition, to further evaluate her nephrotic syndrome, a renal ultrasound-guided biopsy was done. Her kidneys were of normal size. The biopsy showed diabetic nephropathy with extensive nodular glomeruli sclerosis, moderate interstitial fibrosis and mild focal chronic inflammation, mild tubular atrophy, and severe arteriolar hyalinosis. She responded to hemodialysis and her serum creatinine trended down to 1.30mg/dL with resolution of anasarca.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Comparison of laboratory values before and after cystectomy</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Laboratory values</bold>
              </th>
              <th align="left">
                <bold>Before cystectomy</bold>
              </th>
              <th align="left">
                <bold>After cystectomy</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">
                <bold>Total white blood cell (K/UL)</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">Peak 57.8<hr/></td>
              <td align="left" valign="bottom">Peak 6.8<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">
                <bold>Absolute neutrophil count (K/UL)</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">Peak 43.24<hr/></td>
              <td align="left" valign="bottom">Peak 5.05<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">
                <bold>Leukocyte alkaline phosphatase score</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">295<hr/></td>
              <td align="left" valign="bottom">
                <bold>&#x2013;</bold>
                <hr/>
              </td>
            </tr>
            <tr>
              <td align="left" valign="bottom">
                <bold>Erythrocyte sedimentation rate (mm/hour)</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">&gt;140<hr/></td>
              <td align="left" valign="bottom">45<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom"><bold>C</bold>-<bold>reactive protein (mg/dL)</bold><hr/></td>
              <td align="left" valign="bottom">29.5<hr/></td>
              <td align="left" valign="bottom">6.89<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">
                <bold>Antineutrophilic antibody</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">320<hr/></td>
              <td align="left" valign="bottom">&lt;80<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">
                <bold>24-hour urine protein (g)</bold>
                <hr/>
              </td>
              <td align="left" valign="bottom">14.65<hr/></td>
              <td align="left" valign="bottom">5.25<hr/></td>
            </tr>
            <tr>
              <td align="left">
                <bold>Serum creatinine (mg/dL)</bold>
              </td>
              <td align="left">3.27</td>
              <td align="left">1.30</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Graphical representation of the trend of white blood cell counts before and after cystectomy (see arrow).</bold> X axis represents time and Y axis represents white blood cell count in K/UL. Green and blue lines represent the normal range of white blood cell count. Pink line represents the trend in the patient&#x2019;s white blood cell count.</p>
        </caption>
        <graphic xlink:href="1752-1947-8-147-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Positron emission tomography scan showing metabolic activity only in the bladder, prior to cystectomy.</bold> There is no evidence of regional or distant metastasis. There is slight increased activity in the skeletal system which is probably secondary to a marrow stenting agent.</p>
        </caption>
        <graphic xlink:href="1752-1947-8-147-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Computed tomography scan of the pelvis showing large nodular bladder mass with heterogeneous enhancement, prior to cystectomy.</bold> Exchange are most extensive along the right bladder wall though is also seen along the left bladder wall and fundus.</p>
        </caption>
        <graphic xlink:href="1752-1947-8-147-3"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p><bold>Histological examination of the cystectomy specimen showing poorly differentiated high-grade transitional cell carcinoma.</bold> (Hematoxylin and eosin section, original magnification&#xD7;220).</p>
        </caption>
        <graphic xlink:href="1752-1947-8-147-4"/>
      </fig>
      <p>The patient refused adjuvant chemotherapy and returned 3 months following her cystectomy with an elevated WBC (peak WBC 45.3K/UL) and serum creatinine 1.90. A CT scan showed multiple pelvic masses with abdominal lymphadenopathy and a large right pelvic mass in close approximation to the area of the sigmoid colon causing obstruction. Her serum G-CSF level was 406.6pg/mL (normal &lt;39.1pg/mL) confirming the diagnosis of paraneoplastic leukemoid reaction. She underwent a diverting colostomy to relieve symptoms of bowel obstruction. However due to poor performance status, renal failure and the development of a colovaginal fistula, she was placed on palliative care and expired soon thereafter.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>This rare case of urothelial carcinoma of the bladder had several unusual features including young age at presentation, marked leukemoid reaction, elevated G-CSF levels (ten times the normal limit), nephrotic range proteinuria and very rapid progression of disease to death within 6 months of the onset of the leukemoid reaction. Urothelial carcinoma in this case showed squamous differentiation which has been reported to have elevated G-CSF levels [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. A possible mechanism for development of leukemoid reaction and rapid metastatic spread of the tumor is that the high-grade urothelial carcinoma harbored both paraneoplastic production of G-CSF and expression of functional G-CSFR. This may have stimulated the bone marrow with increased myelopoiesis and leukemoid reaction. The stimulation of tumor growth may have been due to the expression of functional G-CSFR by the neoplastic cells, creating a positive feedback cycle. This mechanism has been demonstrated in <italic>in vitro</italic> studies [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Consistent with this mechanism, the above unusual features normalized after removal of the tumor (Table&#xA0;<xref ref-type="table" rid="T1">1</xref> and Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). Similar post-surgical normalization of the leukemoid reaction and G-CSF has been previously observed in bladder cancer [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Three months later, with recurrence of tumor, there was elevated WBC and G-CSF. Hence, G-CSF could be used to follow the evolution of cancer and as a potential future prognostic marker. Of note, this case also exhibited nephrotic range proteinuria which improved after tumor removal, thereby clinically seemed to be paraneoplastic, but biopsy showed features of diabetic nephropathy. Minimal-change glomerulopathy associated with urothelial carcinoma has been rarely reported in the literature [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. However, this may have been masked by her pre-existing diabetic nephropathy.</p>
      <p>In the present case, as the tumor recurred and grew in her pelvic cavity, the concentration of serum G-CSF was elevated with an associated increase in her WBC count. These findings support the hypothesis that the bladder cancer cells producing G-CSF may grow more rapidly or that the G-CSF production exhibited by the tumor cells may promote the malignant progression. We thus undertook a comprehensive review of all studies and similar cases reported to date to explore the above hypothesis. It is also probable that the patient had micrometastatic disease, undetectable by currently existing diagnostic modalities, prior to surgery. Rapid development of metastases within 3 months after surgery may have been invigorated by G-CSF secretion and activation of the G-CSF/G-CSFR biological axis stimulating tumor growth.</p>
      <p>A review by Turalic <italic>et al.</italic> showed that the average age of these patients was 70.1 years and the male to female ratio was 3:2. The WBC was as high as 181,800/mL (average 66,758/mL) and there was an average G-CSF level of 203pg/mL with a mean survival of 5.9 months following surgical therapy in these patients. However, those who received adjuvant chemotherapy reported survivals of &gt;20 months [<xref ref-type="bibr" rid="B4">4</xref>]. An observational study in Japanese patients by Mizutani <italic>et al.</italic> in 1995 showed that 9.2% of bladder tumors had elevated G-CSF levels (mean G-CSF of 328), which positively correlated with an increase in grade and progression of stage of cancer, more so in patients with distant metastasis. Furthermore, patients with bladder cancer without elevated G-CSF had better disease-specific survival rates at 5 years follow-up when compared with those with an elevated level of serum G-CSF [<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>The mechanism responsible for overexpression of G-CSF in bladder cancer is yet to be clearly elucidated. Possibilities include rearrangement of the G-CSF gene occurring within one of the alleles [<xref ref-type="bibr" rid="B16">16</xref>] and intrinsic activation of nuclear factors that work on the promoter region of the G-CSF gene [<xref ref-type="bibr" rid="B17">17</xref>]. Treatment with phorbol ester, interleukin-1 beta, or interferon gamma increased the level of G-CSF, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in an <italic>in vitro</italic> bladder cancer cell line study. This capability to respond to various stimuli implies that numerous regulatory pathways may be involved in the production of cytokines [<xref ref-type="bibr" rid="B18">18</xref>]. Although the mechanism of G-CSF gene overexpression requires further investigation, Chakraborty <italic>et al.</italic> conducted a series of <italic>in vitro</italic> studies which have shown that G-CSFR specifically signals for beta-1 integrin expression, adhesion and invasion of bladder cancer cells which could promote metastasis [<xref ref-type="bibr" rid="B19">19</xref>]. Furthermore, they demonstrated that the G-CSF/G-CSFR biological axis facilitated survival and growth of bladder cancer cells and stimulated STAT3-dependent survivin expression [<xref ref-type="bibr" rid="B11">11</xref>]. The histogenesis of transitional cell carcinoma of the bladder is uncertain, although different theories have been proposed. Some authors have suggested that a metaplastic phenomenon with various degrees of differentiation may be responsible for the malignant transitional cell G-CSF production [<xref ref-type="bibr" rid="B20">20</xref>]. In addition, this theory is supported further by the remarkable potential of the transitional epithelium and transitional cell carcinoma to differentiate into several lines [<xref ref-type="bibr" rid="B21">21</xref>]. The frequent finding of both squamous and glandular differentiation has long been observed in transitional cell carcinoma. Furthermore, the presence of neuroendocrine (small cell) differentiation has also been reported [<xref ref-type="bibr" rid="B22">22</xref>]. Hematopoietic differentiation of transitional cell carcinoma, resulting in the acquirement of G-CSF production and G-CSFR expression, is another possibility supported by our observations. Lastly, G-CSF may be released from the foci of tumor necrosis [<xref ref-type="bibr" rid="B7">7</xref>]. Hence, G-CSF could be a potential screening tool to predict aggressive cancer and hence pursue an early aggressive treatment modality.</p>
      <p>G-CSF administration has been in vogue as an adjunct to the management of granulocytopenias, either with or without prior chemotherapy [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Subsequent studies have further confirmed the efficacy of G-CSF in conjunction with systemic chemotherapy for patients with advanced bladder cancer [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. A few studies recommend G-CSF administration to enhance the tumor-specific cytotoxicity of chemotherapy [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>], to allow dose intensification of chemotherapy [<xref ref-type="bibr" rid="B31">31</xref>-<xref ref-type="bibr" rid="B33">33</xref>] with low myelotoxicity and mucosal toxicity levels [<xref ref-type="bibr" rid="B31">31</xref>]. In contrast, Perez <italic>et al.</italic> reported a case of rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma with G-CSF along with chemotherapy [<xref ref-type="bibr" rid="B7">7</xref>]. Recombinant G-CSF may have both direct and indirect stimulatory effects on the growth of bladder cancer cells <italic>in vitro</italic>. It may stimulate the growth of the residual tumor cells after chemotherapy while it is being used clinically to combat myelosuppression induced by antitumor chemotherapy in bladder cancer [<xref ref-type="bibr" rid="B34">34</xref>]. Due to controversial reports, at this time, we can only advocate that all bladder cancers should be tested for the expression of G-CSFR before using G-CSF, because there is the possibility of growth stimulation by G-CSF if they have G-CSFR on their cell surfaces. With a better understanding of the biology, this autocrine growth signal could be a potential target for therapy in future.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>On the basis of this case experience and review of literature we conclude that there is a distinct and highly aggressive subtype of bladder cancer which secretes G-CSF and expresses G-CSFR inducing an autocrine growth cycle. Hence such patients presenting with leukemoid reaction should be tested for G-CSF/G-CSFR biological axis. Moreover, G-CSF could be a potential neoplastic marker as it can follow the clinical course of the underlying tumor and thus be useful for monitoring its evolution. Neoadjuvant chemotherapy should be considered as the aggressive nature of these tumors appears to overwhelm these patients before they receive adjuvant treatments. With a better understanding of the biology, this autocrine growth signal could be a potential target for therapy in future.</p>
      <p>We are currently planning to conduct a preliminary study to identify patients with such bladder cancer, not only to estimate its prevalence but also to assess the variation in G-CSF levels in response to various therapies (surgery, chemotherapy, radiotherapy). In addition we will evaluate G-CSF as a prognostic marker and as a tool to predict a more aggressive biological phenotype of invasive bladder cancer. Future studies will be necessary to determine the regulatory effects of G-CSF on bladder cancer cells.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient&#x2019;s next of kin for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>ANA: Antineutrophilic antibody; ANC: Absolute neutrophil count; CRP: C-reactive protein; CT: Computed tomography; ESR: Erythrocyte sedimentation rate; G-CSF: Granulocyte colony-stimulating factor; G-CSFR: Granulocyte colony-stimulating factor receptor; WBC: white blood cell.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that we have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>AKLK drafted the manuscript and prepared the figures. PVV, MM and JH reviewed and amended the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>The authors would like to thank Dr Ivan Damjanov, Pathologist at University of Kansas Medical Center, Kansas for providing biopsy descriptions and picture (Figure <xref ref-type="fig" rid="F4">4</xref>).</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tachibana</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miyakawa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tazaki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kubo</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hata</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nishi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Amano</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor</article-title>
          <source>Cancer Res</source>
          <year>1995</year>
          <volume>55</volume>
          <fpage>3438</fpage>
          <lpage>3443</lpage>
          <pub-id pub-id-type="pmid">7542171</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Demetri</surname>
            <given-names>GD</given-names>
          </name>
          <name>
            <surname>Griffin</surname>
            <given-names>JD</given-names>
          </name>
          <article-title>Granulocyte colony-stimulating factor and its receptor</article-title>
          <source>Blood</source>
          <year>1991</year>
          <volume>78</volume>
          <fpage>2791</fpage>
          <lpage>2808</lpage>
          <pub-id pub-id-type="pmid">1720034</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sato</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Terada</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sugiyama</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Masuda</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kakinuma</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kato</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Granulocyte colony-stimulating factor produced by bladder carcinoma of a patient with leukemoid reaction did not affect proliferation of the tumor cells</article-title>
          <source>J Urol</source>
          <year>1994</year>
          <volume>151</volume>
          <fpage>1687</fpage>
          <lpage>1690</lpage>
          <pub-id pub-id-type="pmid">7514696</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Turalic</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Deamant</surname>
            <given-names>FD</given-names>
          </name>
          <name>
            <surname>Reese</surname>
            <given-names>JH</given-names>
          </name>
          <article-title>Paraneoplastic production of granulocyte colony-stimulating factor in a bladder carcinoma</article-title>
          <source>Scand J Urol Nephrol</source>
          <year>2006</year>
          <volume>40</volume>
          <fpage>429</fpage>
          <lpage>432</lpage>
          <pub-id pub-id-type="doi">10.1080/00365590600679350</pub-id>
          <pub-id pub-id-type="pmid">17060092</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hirasawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kitamura</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Oka</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Matsushita</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein</article-title>
          <source>J Urol</source>
          <year>2002</year>
          <volume>167</volume>
          <fpage>2130</fpage>
          <pub-id pub-id-type="doi">10.1016/S0022-5347(05)65104-X</pub-id>
          <pub-id pub-id-type="pmid">11956459</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McRae</surname>
            <given-names>SN</given-names>
          </name>
          <name>
            <surname>Gilbert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Deamant</surname>
            <given-names>FD</given-names>
          </name>
          <name>
            <surname>Reese</surname>
            <given-names>JH</given-names>
          </name>
          <article-title>Poorly differentiated carcinoma of bladder producing granulocyte colony-stimulating factor and parathyroid hormone related protein</article-title>
          <source>J Urol</source>
          <year>2001</year>
          <volume>165</volume>
          <fpage>527</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="doi">10.1097/00005392-200102000-00049</pub-id>
          <pub-id pub-id-type="pmid">11176419</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Perez</surname>
            <given-names>FA</given-names>
          </name>
          <name>
            <surname>Fligner</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>EY</given-names>
          </name>
          <article-title>Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>e215</fpage>
          <lpage>e217</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.22.4931</pub-id>
          <pub-id pub-id-type="pmid">19786665</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mizutani</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Okada</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Terachi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kakehi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yoshida</surname>
            <given-names>O</given-names>
          </name>
          <article-title>Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies</article-title>
          <source>Br J Urol</source>
          <year>1995</year>
          <volume>76</volume>
          <fpage>580</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1464-410X.1995.tb07782.x</pub-id>
          <pub-id pub-id-type="pmid">8535676</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ohigashi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Tachibana</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tazaki</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Bladder cancer cells express functional receptors for granulocyte-colony stimulating factor</article-title>
          <source>J Urol</source>
          <year>1992</year>
          <volume>147</volume>
          <fpage>283</fpage>
          <lpage>286</lpage>
          <pub-id pub-id-type="pmid">1370331</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tachibana</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Miyakawa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Uchida</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Murai</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Eguchi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nakamura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kubo</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hata</surname>
            <given-names>JI</given-names>
          </name>
          <article-title>Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder</article-title>
          <source>Br J Cancer</source>
          <year>1997</year>
          <volume>75</volume>
          <fpage>1489</fpage>
          <lpage>1496</lpage>
          <pub-id pub-id-type="doi">10.1038/bjc.1997.254</pub-id>
          <pub-id pub-id-type="pmid">9166942</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chakraborty</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Guha</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells</article-title>
          <source>Urology</source>
          <year>2007</year>
          <volume>69</volume>
          <fpage>1210</fpage>
          <lpage>1215</lpage>
          <pub-id pub-id-type="doi">10.1016/j.urology.2007.02.035</pub-id>
          <pub-id pub-id-type="pmid">17572226</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sires</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Neely</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Skinner</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Leukemoid reaction in a patient with bladder and prostatic cancer</article-title>
          <source>J Urol</source>
          <year>1986</year>
          <volume>135</volume>
          <fpage>366</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">3944874</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Stav</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Leibovici</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Siegel</surname>
            <given-names>YI</given-names>
          </name>
          <name>
            <surname>Lindner</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Leukemoid reaction associated with transitional cell carcinoma</article-title>
          <source>Isr Med Assoc J</source>
          <year>2002</year>
          <volume>4</volume>
          <fpage>223</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">11908271</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Martinez-Vea</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Panisello</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Garcia</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cases</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Torras</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mayayo</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Carrera</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Richart</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Oliver</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>Minimal-change glomerulopathy and carcinoma. Report of two cases and review of the literature</article-title>
          <source>Am J Nephrol</source>
          <year>1993</year>
          <volume>13</volume>
          <fpage>69</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1159/000168592</pub-id>
          <pub-id pub-id-type="pmid">8322844</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cases</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Torras</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lens</surname>
            <given-names>XM</given-names>
          </name>
          <name>
            <surname>Revert</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Minimal-change nephrotic syndrome associated with an undifferentiated urothelial carcinoma</article-title>
          <source>Med Clin (Barc)</source>
          <year>1986</year>
          <volume>86</volume>
          <fpage>436</fpage>
          <pub-id pub-id-type="pmid">3713303</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>George</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Griffin</surname>
            <given-names>JD</given-names>
          </name>
          <article-title>Granulocyte colony stimulating factor and its receptor. <italic>Blood</italic> 1991, 78:2791&#x2013;2795 (cited by Mizutani Y, Okada Y, Terachi T, Kakehi Y, Yoshida O: Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies</article-title>
          <source>Br J Urol</source>
          <year>1995</year>
          <volume>76</volume>
          <fpage>580</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1464-410X.1995.tb07782.x</pub-id>
          <pub-id pub-id-type="pmid">8535676</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nishizawa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tsuchiya</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Watanabe-Fukunaga</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Nagata</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Multiple elements in the promoter of granulocyte colony-stimulating factor gene regulate its constitutive expression in human carcinoma cells</article-title>
          <source>J Biol Chem</source>
          <year>1990</year>
          <volume>265</volume>
          <fpage>5897</fpage>
          <lpage>5902</lpage>
          <pub-id pub-id-type="pmid">1690717</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Steube</surname>
            <given-names>KG</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Tachibana</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Murai</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Drexler</surname>
            <given-names>HG</given-names>
          </name>
          <article-title>Bladder carcinoma cell line KU-19-19-derived cytokines support proliferation of growth factor-dependent hematopoietic cell lines: modulation by phorbol ester, interferon-gamma and interleukin-1 beta</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>1998</year>
          <volume>242</volume>
          <fpage>497</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="doi">10.1006/bbrc.1997.8002</pub-id>
          <pub-id pub-id-type="pmid">9464244</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chakraborty</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>White</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Guha</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Granulocyte colony-stimulating receptor promotes beta1-integrin-mediated adhesion and invasion of bladder cancer cells</article-title>
          <source>Urology</source>
          <year>2006</year>
          <volume>68</volume>
          <fpage>208</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="pmid">16844458</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Iles</surname>
            <given-names>RK</given-names>
          </name>
          <name>
            <surname>Chard</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Human chorionic gonadotropin expression by bladder cancers: biology and clinical potential</article-title>
          <source>J Urol</source>
          <year>1991</year>
          <volume>145</volume>
          <fpage>453</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="pmid">1705292</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Grammatico</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Grignon</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Eberwein</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Shepherd</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Hearn</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Walton</surname>
            <given-names>JC</given-names>
          </name>
          <article-title>Transitional cell carcinoma of the renal pelvis with choriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder</article-title>
          <source>Cancer</source>
          <year>1993</year>
          <volume>71</volume>
          <fpage>1835</fpage>
          <lpage>1841</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19930301)71:5&lt;1835::AID-CNCR2820710519&gt;3.0.CO;2-5</pub-id>
          <pub-id pub-id-type="pmid">8448745</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Grignon</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Ro</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Ayala</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Shum</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Ordonez</surname>
            <given-names>NG</given-names>
          </name>
          <name>
            <surname>Logothetis</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>DE</given-names>
          </name>
          <name>
            <surname>Mackay</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases</article-title>
          <source>Cancer</source>
          <year>1992</year>
          <volume>69</volume>
          <fpage>527</fpage>
          <lpage>536</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19920115)69:2&lt;527::AID-CNCR2820690241&gt;3.0.CO;2-7</pub-id>
          <pub-id pub-id-type="pmid">1309435</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gabrilove</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Jakubowski</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Scher</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sternberg</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Grous</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Yagoda</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fain</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Clarkson</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Oettgen</surname>
            <given-names>HF</given-names>
          </name>
          <name>
            <surname>Alton</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Welte</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Souza</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium</article-title>
          <source>N Engl J Med</source>
          <year>1988</year>
          <volume>318</volume>
          <fpage>1414</fpage>
          <lpage>1422</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM198806023182202</pub-id>
          <pub-id pub-id-type="pmid">2452983</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Crawford</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ozer</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Stoller</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lyman</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tabbara</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Kris</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Grous</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Picozzi</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Rausch</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gradishar</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Yahanda</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Vincent</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Glaspy</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>1991</year>
          <volume>325</volume>
          <fpage>164</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199107183250305</pub-id>
          <pub-id pub-id-type="pmid">1711156</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Morstyn</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Souza</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Alton</surname>
            <given-names>NK</given-names>
          </name>
          <name>
            <surname>Keech</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sheridan</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Metcalf</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Fox</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy</article-title>
          <source>Lancet</source>
          <year>1988</year>
          <volume>1</volume>
          <fpage>667</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="pmid">2895212</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ohno</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Tomonaga</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kobayashi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kanamaru</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Shirakawa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Masaoka</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Omine</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Oh</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Nomura</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Sakai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hirano</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yokomaku</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nakayama</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yoshida</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Miura</surname>
            <given-names>AB</given-names>
          </name>
          <name>
            <surname>Morishima</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Dohy</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Niho</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hamajima</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Takaku</surname>
            <given-names>F</given-names>
          </name>
          <article-title>Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia</article-title>
          <source>N Engl J Med</source>
          <year>1990</year>
          <volume>323</volume>
          <fpage>871</fpage>
          <lpage>877</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199009273231304</pub-id>
          <pub-id pub-id-type="pmid">1697646</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Aso</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Akaza</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer. Urological rhG-CSF Study Group</article-title>
          <source>J Urol</source>
          <year>1992</year>
          <volume>147</volume>
          <fpage>1060</fpage>
          <lpage>1064</lpage>
          <pub-id pub-id-type="pmid">1372661</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Miyanaga</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Akaza</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shimazui</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ohtani</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Koiso</surname>
            <given-names>K</given-names>
          </name>
          <article-title>The effect of dose intensity on M-VAC therapy for advanced urothelial cancer</article-title>
          <source>Cancer Chemother Pharmacol</source>
          <year>1994</year>
          <volume>35</volume>
          <issue>Suppl</issue>
          <fpage>S5</fpage>
          <lpage>S8</lpage>
          <pub-id pub-id-type="pmid">7527735</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ohigashi</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Granulocyte-colony stimulating factor enhances the cytotoxic effects of methotrexate to bladder cancer cells in vitro</article-title>
          <source>Keio J Med</source>
          <year>1990</year>
          <volume>39</volume>
          <fpage>254</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.2302/kjm.39.254</pub-id>
          <pub-id pub-id-type="pmid">1704940</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Akaza</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Fukushima</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Koiso</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Aso</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Enhancement of chemotherapeutic effects by recombinant human granulocyte colony-stimulating factor on implanted mouse bladder cancer cells (MBT-2)</article-title>
          <source>Cancer</source>
          <year>1992</year>
          <volume>69</volume>
          <fpage>997</fpage>
          <lpage>1002</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19920215)69:4&lt;997::AID-CNCR2820690428&gt;3.0.CO;2-U</pub-id>
          <pub-id pub-id-type="pmid">1370920</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Viens</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Gravis</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bladou</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lechevallier</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Baume</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Camerlo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cowen</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Coulange</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Serment</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Resbeut</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Maraninchi</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma</article-title>
          <source>Eur Cytokine Netw</source>
          <year>1996</year>
          <volume>7</volume>
          <fpage>395</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="pmid">8954183</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pronzato</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bertelli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bruna</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Tani</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Vaira</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Vanoli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Vigani</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer</article-title>
          <source>Anticancer Res</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>2325</fpage>
          <lpage>2327</lpage>
          <pub-id pub-id-type="pmid">9216710</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal">
          <name>
            <surname>de Wit</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Overview of bladder cancer trials in the European Organization for Research and Treatment</article-title>
          <source>Cancer</source>
          <year>2003</year>
          <volume>97</volume>
          <fpage>2120</fpage>
          <lpage>2126</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.11288</pub-id>
          <pub-id pub-id-type="pmid">12673705</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shameem</surname>
            <given-names>IA</given-names>
          </name>
          <name>
            <surname>Kurisu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Matsuyama</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shimabukuro</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Naito</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on <italic>in vitro</italic> colony formation of human bladder cancer cells</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>1994</year>
          <volume>38</volume>
          <fpage>353</fpage>
          <lpage>357</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01517203</pub-id>
          <pub-id pub-id-type="pmid">7515769</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
